[The latest progestagens].
The new progestative molecules have allowed to reduce the doses of steroids in the combined pills. They have a reduced androgenic activity allowing the positive effects of ethinyl estradiol to act on lipid metabolisms, which may lead to a reduction of atherogenesis. However these new pills should not be administered if the classical contraindications exist. On the contrary the strong gonadotropic effect of the latest nor-pregnane derivates can be used (the chlormadinone as well) on patients with thromboembolic history on the condition that the still partially experimental aspect of this mode of contraception is taken into consideration.